Latest Period
Q1 2026
Security Snapshot
Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NMRA) Institutional Ownership
CUSIP: 640979100
13F Institutional Holders and Ownership History from Q3 2023 to Q1 2026
Institutions Reporting
112
Shares (Excl. Options)
70,388,932
Price
$1.95
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- NMRA on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 70,388,932
- Total 13F value
- $137,245,288
- Portfolio coverage rank
- 0%
- Share change
- +7,345,030
- Value change
- +$14,527,234
- Number of holders
- 112
- Shares outstanding
- 186,788,806
- SEC-reported price per share
- $1.95
- Insider filing price
- $1.95
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- NMRA - Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 640979100.
- 112 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 101 to 112 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $112,659,237 to $137,245,288.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 112 institutions filings for Q1 2026.
Security key
640979100
Latest holder period
Q1 2026
13F holders
112
13D/G owners
5
CIK / CUSIP context first
Open Q1 2026 holders
NMRA full holder history
Neumora Therapeutics, Inc. SEC filings
Neumora Therapeutics, Inc. company facts
Neumora Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 640979100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
NMRA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARCH Venture Fund XII, L.P. | 19% | -9.5% | $69,289,455 | +$13,162 | 33,965,419 | +0.02% | Kristina Burow | 30 Mar 2026 |
| Invus Global Management, LLC | 4.7% | -14% | $16,570,753 | -$975,000 | 8,497,822 | -5.6% | Raymond Debbane | 31 Mar 2026 |
| BERNS PAUL L | 5.1% | $6,334,229 | 8,226,272 | Paul L Berns | 31 Dec 2024 | |||
| K2 HealthVentures Equity Trust LLC | 3.1% | -38% | $11,291,383 | -$6,252,835 | 5,790,453 | -36% | K2 HealthVentures Equity Trust LLC | 31 Mar 2026 |
| FMR LLC | 2.2% | $2,692,163 | 3,496,316 | FMR LLC | 31 Mar 2025 |
As of 31 Mar 2026, 112 institutional investors reported holding 70,388,932 shares of Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NMRA). This represents 38% of the company’s total 186,788,806 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
32%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Siren, L.L.C. | 4.5% | 8,497,822 | +35% | 0.46% | $16,570,753 |
| SOFTBANK GROUP CORP. | 3.3% | 6,090,301 | -5.3% | 0.1% | $11,876,087 |
| PERCEPTIVE ADVISORS LLC | 2.7% | 5,104,097 | 0.2% | $9,952,989 | |
| MIC Capital Management UK LLP | 2.4% | 4,460,700 | 0% | 2.5% | $8,698,365 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.1% | 3,891,893 | 0% | 0% | $7,589,191 |
| FMR LLC | 1.9% | 3,498,658 | +0.01% | 0% | $6,822,383 |
| WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | 1.8% | 3,309,123 | 0% | 0.08% | $6,452,790 |
| MILLENNIUM MANAGEMENT LLC | 1.5% | 2,754,854 | -24% | 0% | $5,371,965 |
| ICONIQ Capital, LLC | 1.4% | 2,559,090 | 0% | 0.11% | $4,990,226 |
| Lunate Capital Ltd | 1.1% | 2,124,143 | 0% | 3.4% | $4,142,079 |
| BlackRock, Inc. | 1.1% | 2,054,316 | +1.5% | 0% | $4,005,917 |
| TWO SIGMA INVESTMENTS, LP | 1.1% | 2,036,692 | +56% | 0% | $3,971,549 |
| JOHNSON & JOHNSON | 0.99% | 1,849,445 | 0% | 0.55% | $3,606,418 |
| RENAISSANCE TECHNOLOGIES LLC | 0.74% | 1,388,998 | -3.9% | 0% | $2,708,546 |
| Ikarian Capital, LLC | 0.68% | 1,278,408 | 0% | 0.36% | $2,492,896 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.66% | 1,240,241 | +68% | 0% | $2,418,470 |
| MARSHALL WACE, LLP | 0.64% | 1,195,310 | +105% | 0% | $2,330,856 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.58% | 1,086,865 | +8.3% | 0% | $2,120,406 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.54% | 1,000,000 | 0% | $1,950,000 | |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.44% | 818,156 | 0.19% | $1,595,404 | |
| TUDOR INVESTMENT CORP ET AL | 0.41% | 771,418 | 0.01% | $1,504,265 | |
| JANE STREET GROUP, LLC | 0.4% | 747,665 | -34% | 0% | $1,457,947 |
| AlphaCore Capital LLC | 0.34% | 638,784 | 0% | 0.03% | $1,245,629 |
| Point72 Asset Management, L.P. | 0.32% | 602,403 | -84% | 0% | $1,174,686 |
| GOLDMAN SACHS GROUP INC | 0.3% | 568,280 | -34% | 0% | $1,108,146 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
11
Latest
Q1 2026
Rows shown
1-11 of 11
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 70,388,932 | $137,245,288 | +$14,527,234 | $1.95 | 112 |
| 2025 Q4 | 62,936,237 | $112,659,237 | +$21,661,237 | $1.79 | 101 |
| 2025 Q3 | 50,688,208 | $92,241,263 | -$7,574,740 | $1.82 | 91 |
| 2025 Q2 | 56,105,109 | $41,177,547 | -$6,520,439 | $0.73 | 96 |
| 2025 Q1 | 65,233,736 | $65,235,367 | -$163,396,114 | $1.00 | 111 |
| 2024 Q4 | 80,333,766 | $851,575,296 | +$93,329,557 | $10.60 | 132 |
| 2024 Q3 | 68,678,182 | $907,013,068 | +$21,361,695 | $13.21 | 103 |
| 2024 Q2 | 63,827,298 | $627,414,966 | +$100,142,866 | $9.83 | 92 |
| 2024 Q1 | 52,696,596 | $725,374,900 | +$114,726,209 | $13.75 | 86 |
| 2023 Q4 | 43,747,888 | $744,815,306 | +$130,275,365 | $17.05 | 60 |
| 2023 Q3 | 36,353,167 | $512,042,809 | +$512,042,809 | $14.11 | 38 |